gvtcx

NHS London Branded Medicines - Tranche B - September 2023

NHS England Published 8 Aug 2023 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£445,752,000
Statuscomplete
Category (CPV) 33600000
Deadline17 Apr 2023
Procedureopen
OCIDocds-h6vhtk-03b23b

Awards (72)

This procurement was awarded to 38 suppliers. Values shown are per-award; the notice total is £445,752,000.

SupplierValueDateStatus
Abbvie Ltd shared £231,083,000 13 Jul 2023 active
Abbvie Ltd shared · · active
Accord-UK Ltd shared £231,083,000 13 Jul 2023 active
Accord-UK Ltd shared · · active
Almirall shared £231,083,000 13 Jul 2023 active
Almirall shared · · active
AstraZeneca shared £231,083,000 13 Jul 2023 active
AstraZeneca shared · · active
Aventis Pharma ltd t/a Sanofi shared £231,083,000 13 Jul 2023 active
Aventis Pharma ltd t/a Sanofi shared · · active
Bayer Plc shared £231,083,000 13 Jul 2023 active
Bayer Plc shared · · active
Biogen shared £231,083,000 13 Jul 2023 active
Biogen shared · · active
Celltrion Healthcare United Kingdom Limited shared £231,083,000 13 Jul 2023 active
Celltrion Healthcare United Kingdom Limited shared · · active
CST Pharma Limited shared £231,083,000 13 Jul 2023 active
CST Pharma Limited shared · · active
Eli Lilly and Company Ltd shared · · active
Eli Lilly & Company Ltd shared £231,083,000 13 Jul 2023 active
Galapagos Biotech UK Ltd shared £231,083,000 13 Jul 2023 active
Galapagos Biotech UK Ltd shared · · active
Gedeon Richter UK Ltd shared £231,083,000 13 Jul 2023 active
Gedeon Richter UK Ltd shared · · active
Gilead Sciences Limited shared £231,083,000 13 Jul 2023 active
Gilead Sciences Limited shared · · active
GlaxoSmithKline UK Limited shared £231,083,000 13 Jul 2023 active
GlaxoSmithKline UK Limited shared · · active
Ipsen shared £231,083,000 13 Jul 2023 active
Ipsen shared · · active
Janssen-Cilag Ltd shared £231,083,000 13 Jul 2023 active
Janssen-Cilag Ltd shared · · active
Kent Pharma Ltd shared £231,083,000 13 Jul 2023 active
Kent Pharma Ltd shared · · active
Merck Serono Limited shared £231,083,000 13 Jul 2023 active
Merck Serono Limited shared · · active
Merck Sharpe and Dohme (UK) Limited shared · · active
Merck Sharpe & Dohme (UK) Limited shared £231,083,000 13 Jul 2023 active
Mylan shared £231,083,000 13 Jul 2023 active
Mylan shared · · active
Neon Healthcare Ltd shared £231,083,000 13 Jul 2023 active
Neon Healthcare Ltd shared · · active
Novartis Pharmaceuticals UK Ltd shared £231,083,000 13 Jul 2023 active
Novartis Pharmaceuticals UK Ltd shared · · active
Novo Nordisk shared £231,083,000 13 Jul 2023 active
Novo Nordisk shared · · active
Organon Pharmaceuticals UK Ltd shared £231,083,000 13 Jul 2023 active
Organon Pharmaceuticals UK Ltd shared · · active
Orifarm UK shared £231,083,000 13 Jul 2023 active
Orifarm UK shared · · active
Pfizer Ltd shared £231,083,000 13 Jul 2023 active
Pfizer Ltd shared · · active
Roche Products Ltd shared £231,083,000 13 Jul 2023 active
Roche Products Ltd shared · · active
Sandoz Ltd shared £231,083,000 13 Jul 2023 active
Sandoz Ltd shared · · active
Sobi (Swedish Orphan Biovitrum Ltd) shared £231,083,000 13 Jul 2023 active
Sobi (Swedish Orphan Biovitrum Ltd) shared · · active
Sun Pharma UK Ltd shared £231,083,000 13 Jul 2023 active
Sun Pharma UK Ltd shared · · active
Takeda UK Ltd shared £231,083,000 13 Jul 2023 active
Takeda UK Ltd shared · · active
Teva UK Limited shared £231,083,000 13 Jul 2023 active
Teva UK Limited shared · · active
Thornton and Ross Ltd shared £231,083,000 13 Jul 2023 active
Thornton and Ross Ltd shared · · active
Typharm Ltd shared £231,083,000 13 Jul 2023 active
Typharm Ltd shared · · active
UCB Pharma Ltd shared £231,083,000 13 Jul 2023 active
UCB Pharma Ltd shared · · active
Zentiva Pharma UK Ltd shared £231,083,000 13 Jul 2023 active
Zentiva Pharma UK Ltd shared · · active

description

Project Title: NHS London Branded Medicines - Tranche B - September 2023<br/><br/>Offer reference number: CM/PHR/22/5677<br/><br/>CM/PHR/22/5677/01 - NHS Framework for London Branded Medicines - Tranche B. Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/><br/>CM/PHR/22/5677/02 - NHS Framework for London Branded Medicines - Annual Tranche. Period of framework: 1 September 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

5 notices published against this procurement.

PublishedTypeRegimeNotice
7 Dec 2022 Planning (planning) · fd9f4267-35ab-4823-bcde-5d032a7358d1-596728
13 Mar 2023 Contract notice (F02) Earlier regulations 007212-2023
13 Mar 2023 Tender (tender) · 2dd7a286-9f43-4efa-95bb-147a6e1d1d37-623538
8 Aug 2023 Contract award notice (F03) Earlier regulations 023090-2023
11 Aug 2023 Award (award) · 3cb166f4-d32d-4d24-ba5f-9127da489fc3-671149

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.